One-stop Patient Support
Chiesi Total CareSM provides your patients with the exceptional support they need, when and where they need it. To enroll, download and complete the enrollment form below.
A single call to your dedicated Chiesi Total Care team and the completed Prescription/Nursing Order Form is all it takes to begin the process of getting a patient started on Lamzede® (velmanase alfa-tycv) therapy.*
| * | Chiesi Total Care provides nonfinancial assistance to patients with and without prescription drug coverage. Government-funded plans are not eligible for patient support services that provide financial support through the programs. If your patient is receiving treatment or residing in MA or RI, they are not eligible for infusion assistance. Please see the full Terms and Conditions for additional eligibility requirements. |
For billing and coding information, and assistance getting your patient's Lamzede treatment covered by their insurance, see the Access Resource Guide.
Call toll free:
1-855-282-4883
WARNING: SEVERE HYPERSENSITIVITY REACTIONS
Hypersensitivity Reactions Including Anaphylaxis
Patients treated with Lamzede have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Lamzede administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue Lamzede immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Lamzede may be considered.
The Chiesi Total Care Program Assists With:
Commercial insurance
If your patients have private insurance through their job or their own business.
Government insurance
If your patients have Medicare, Medicaid, Veterans Affairs Healthcare, or other similar government insurance.
No insurance
If your patients have no insurance, they may be eligible for additional financial assistance.
Dedicated Total Care team:
- Pharmacists
- Patient service coordinators
- Reimbursement support specialists
- Nursing support
Infusion assistance†
- Ensures medication is delivered right to where your patients need it
- Assists you in finding an appropriate infusion facility
- Answers questions about administration, storage and disposal, and more
- Reviews eligibility for home infusion assistance†
Routine testing
Healthcare providers should consider monitoring for the presence of serum oligosaccharides reduction and anti-drug antibodies in patients who demonstrate hypersensitivity reactions and should consider the risks and benefits of continued treatment in patients with serum oligosaccharides reduction and anti-Lamzede antibodies. There are no marketed tests for these antibodies against Lamzede. If monitoring is warranted, Chiesi Total Care may be able to help.
| † | Patients receiving treatment or residing in MA or RI are not eligible for infusion assistance. To receive home infusion support, patient must be referred to home infusion by their prescribing physician. Please refer to the full Terms and Conditions for additional eligibility requirements. |
Downloadable Forms
Contact Information
Phone
1-855-282-4883
Fax
1-855-929-2828
Hours of operation
Monday to Friday
7:00 AM – 6:00 PM (Central Time)
Location
17877 Chesterfield Airport Road
Chesterfield, MO 63005
Helpful Links for Your Patients
For more information about Lamzede® (velmanase alfa-tycv), visit Lamzede.com.
Important Safety Information
WARNING: SEVERE HYPERSENSITIVITY REACTIONS
Hypersensitivity Reactions Including Anaphylaxis
Patients treated with Lamzede have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Lamzede administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue Lamzede immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Lamzede may be considered.
Considerations Due to Hypersensitivity Reactions and/or Infusion-Associated Reactions (IARs)
Prior to Lamzede administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and IARs and instruct them to seek medical care immediately if such symptoms occur.
| • | If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Lamzede administration and initiate appropriate medical treatment. |
| • | In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, consider temporarily holding the infusion for 15 to 30 minutes, slowing the infusion rate to 25% to 50% of the recommended rate, and initiating appropriate medical treatment. |
Hypersensitivity Reactions Including Anaphylaxis
Anaphylaxis and severe hypersensitivity signs and symptoms included cyanosis, hypotension, emesis, urticaria, erythema, facial swelling, pyrexia, and tremor.
Infusion-Associated Reactions (IARs)
The most frequent symptoms of IARs that occurred in >10% of the population were pyrexia, chills, erythema, vomiting, cough, urticaria, rash, and conjunctivitis.
Females of Reproductive Potential
Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if Lamzede is discontinued. For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with Lamzede.
Embryo-Fetal Toxicity
Based on findings from animal reproduction studies, Lamzede may cause embryo-fetal harm when administered to a pregnant female.
Common Adverse Reactions
The most common adverse reactions (incidence >20%) are hypersensitivity reactions including anaphylaxis, nasopharyngitis, pyrexia, headache, and arthralgia.
Please see Full Prescribing Information for Lamzede.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Indication
Lamzede® (velmanase alfa-tycv) is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.
Please see Full Prescribing Information for Lamzede.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Important Safety Information
WARNING: SEVERE HYPERSENSITIVITY REACTIONS
Hypersensitivity Reactions Including Anaphylaxis
Patients treated with Lamzede have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Lamzede administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue Lamzede immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Lamzede may be considered.
Considerations Due to Hypersensitivity Reactions and/or Infusion-Associated Reactions (IARs)
Prior to Lamzede administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and IARs and instruct them to seek medical care immediately if such symptoms occur.
| • | If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Lamzede administration and initiate appropriate medical treatment. |
| • | In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, consider temporarily holding the infusion for 15 to 30 minutes, slowing the infusion rate to 25% to 50% of the recommended rate, and initiating appropriate medical treatment. |
Hypersensitivity Reactions Including Anaphylaxis
Anaphylaxis and severe hypersensitivity signs and symptoms included cyanosis, hypotension, emesis, urticaria, erythema, facial swelling, pyrexia, and tremor.
Infusion-Associated Reactions (IARs)
The most frequent symptoms of IARs that occurred in >10% of the population were pyrexia, chills, erythema, vomiting, cough, urticaria, rash, and conjunctivitis.
Females of Reproductive Potential
Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if Lamzede is discontinued. For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with Lamzede.
Embryo-Fetal Toxicity
Based on findings from animal reproduction studies, Lamzede may cause embryo-fetal harm when administered to a pregnant female.
Common Adverse Reactions
The most common adverse reactions (incidence >20%) are hypersensitivity reactions including anaphylaxis, nasopharyngitis, pyrexia, headache, and arthralgia.
Please see Full Prescribing Information for Lamzede.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Indication
Lamzede® (velmanase alfa-tycv) is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.
Please see Full Prescribing Information for Lamzede.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.